Evidence map›Paper›PMID 41415033›Full record

ArticleTransplantation direct2026

Consensus-based Recommendations on the Management of Immunosuppression After Squamous Cell Carcinoma Diagnosis in Kidney Transplant Recipients: An International Delphi Consensus Statement.

Melodi Javid Whitley, Jake X Wang, Jeremy Chapman, Aiko P J de Vries, Sindhu Chandran, Colleen M Glennon, Hector M Madariaga, Robert P Carroll, John Booth, Beatrice Concepcion and 29 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Skin Cancer in Solid Organ Transplant Recipients: A Review.American journal of clinical dermatology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Melodi Javid WhitleyDepartment of Dermatology, Duke University School of Medicine, Durham, NC.
Jake X WangDepartment of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH.ORCID https://orcid.org/0000-0003-2023-1861
Jeremy ChapmanConsultant Emeritus, Renal Unit, Westmead Hospital, Westmead, NSW, Australia.
Aiko P J de VriesLeiden Transplant Center, Division of Nephrology, Department of Medicine, Leiden University Medical Center and Leiden University, Leiden, the Netherlands.
Sindhu ChandranDepartment of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Colleen M GlennonDepartment of Dermatology, Duke University School of Medicine, Durham, NC.
Hector M MadariagaDepartment of Medicine, Tufts University School of Medicine, Burlington, MA.
Robert P CarrollTransplantation Immunogenetics Service, Lifeblood, Australian Redcross Blood Service, Sydney, NSW, Australia.
John BoothBarts Health NHS Trust, Royal London Hospital, London, United Kingdom.
Beatrice ConcepcionSection of Nephrology, Department of Medicine, The University of Chicago, Chicago, IL.
Lionel CouziDepartment of Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux University Hospital, Bordeaux, France.
Sacha A De SerresRenal Division, Department of Medicine, Laval University, Quebec, QC, Canada.
Alden DoyleDivision of Nephrology, University of Virginia Health System, Charlottesvilla, VA.
Suzanne ForbesDepartment of Nephrology and Transplantation, The Royal London Hospital, Bart's Health NHS Trust, London, United Kingdom.
Jonathan M GleadleDepartment of Renal Medicine, Southern Adelaide Local Health Network, Flinders Medical Centre, Bedford Park, SA, Australia.
Sian GriffinUniversity Hospital of Wales, Cardiff, United Kingdom.
Lakshman GunaratnamMatthew Mailing Centre for Translational Transplant Studies, Multi-Organ Transplant Program, London Health Sciences Centre, London, ON, Canada.
Gaurav GuptaDivision of Nephrology, Virginia Commonwealth University, Richmond, VA.
Julie HoDepartment of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Peter HughesDepartment of Nephrology, The Royal Melbourne Hospital, Parkville, VIC, Australia.
Nicole IsbelDepartment of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Dev K JegatheesanDepartment of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Gareth JonesUniversity College London Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom.
Dirk KuypersDepartment of Nephrology and Renal Transplantation, University Hospitals Leuven, University of Leuven, Leuven, Belgium.
Brian LeeDivision of Nephrology, Department of Medicine, University of Texas at Austin, Austin, TX.
Wai LimMedical School, University of Western Australia, Perth, WA, Australia.
Phil MasonOxford Transplant Centre, The Churchill Hospital, Oxford, United Kingdom.
Maria MeneghiniNephrology and Kidney Transplantation Laboratory, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain; Department of Nephrology and Kidney Transplantation, University Hospital Vall d'Hebron, Barcelona, Spain.
Itunu OwoyemiDepartment of Kidney Medicine, Cleveland Clinic, Cleveland, OH.
Swati RaoDivision of Nephrology, University of Virginia Health System, Charlottesvilla, VA.
Alan SalamaUniversity College of London Centre for Kidney and Bladder Health, Division of Medicine, Faculty of Medical Sciences, University College London, London, UK.
Adnan SharifDepartment of Nephrology, University Hospitals Birmingham, Birmingham, UK.
Olivier ThaunatService de Transplantation, Néphrolgie et Immunologie Clinique, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
Raj ThuraisinghamDepartment of Renal Medicine and Transplantation, Barts Health NHS Trust, London, UK.
Kate WyburnDepartment of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Julie M YabuDivision of Nephrology, Department of Medicine, University of California, Los Angeles, CA.
Anokhi Jambusaria-PahlajaniDivision of Dermatology, Dell Medical School, University of Texas at Austin, Austin, TX.
Matthew J BottomleyChinese Academy of Medical Sciences (CAMS) Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID https://orcid.org/0000-0001-5793-4777
Sarah T ArronPeninsula Dermatology Medical Group, Burlingame, CA.

Funding

Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

Background: Posttransplant immunosuppression in kidney transplant recipients is associated with an increased risk of developing cutaneous squamous cell carcinoma (CSCC), contributing to significant morbidity and mortality. Various dermatological and immunosuppression modulation strategies have been identified that may reduce the risk of CSCC, both in primary and secondary prevention settings. Recent recommendations have provided consensus regarding dermatological approaches to prevent CSCC. Comparable transplant nephrology recommendations to guide immunosuppression modulation for CSCC prevention are currently lacking, leading to marked variation in practice. Methods: To address this knowledge gap, 46 international transplant nephrology experts participated in a 3-round Delphi survey to develop consensus recommendations for CSCC secondary prevention based on the actinic damage and skin cancer index stages of CSCC. Results: The panel of experts reached consensus to consider a change in immunosuppression after multiple low-risk invasive CSCC (stage 5a, 1/y >3 y) and encouraged collaboration with dermatology to optimize dermatologic preventative care after the first CSCC. There was also consensus to prioritize azathioprine modification where this is present in an immunosuppressive regimen. Conclusions: This study provides the first international consensus recommendations for management of immunosuppression in kidney transplant recipients at discrete stages of CSCC. Additional prospective studies are necessary to determine the optimal management of immunosuppression in this patient population. These recommendations have been endorsed by the Board of the American Society of Transplantation.

Identifiers

PMID41415033
PMCPMC12711373

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.